Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): A clinical, ultrasound, and biomarker-based effectiveness after discontinuation and reinitiation of biosimilar infliximab
{{output}}
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting synovial joints. Biosimilar disease-modifying anti-rheumatic drugs offer cost-effective alternatives to originator biologics for RA treatment but remain expensive for long-term use. This pro... ...
